Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV
Status:
Recruiting
Trial end date:
2028-05-31
Target enrollment:
Participant gender:
Summary
Study purpose: To compare the efficacy and safety of pegylated interferon α-2b in combination
with ruxolitinib versus pegylated interferon α-2b alone for treating hydroxyurea-resistant or
hydroxyurea-intolerant polycythemia vera.